Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Timolol
Drug ID BADD_D02219
Description Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Indications and Usage Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure.[L6724,L6727] In certain cases, timolol is used in the prevention of migraine headaches.[A179530,L6742]
Marketing Status approved
ATC Code C07AA06; S01ED01
DrugBank ID DB00373
KEGG ID D00378; D08600
MeSH ID D013999
PubChem ID 33624
TTD Drug ID D05UVD
NDC Product Code 82584-001; 82584-002; 76478-001; 17478-189; 76478-002
UNII 817W3C6175
Synonyms Timolol | Timolol Maleate | Timolol Maleate, (1:1) Salt | (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol | 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- | Timoptic | Timoptol | Timacar | Timolol Hemihydrate | Blocadren | L-714,465 | L 714,465 | L714,465 | MK-950 | MK 950 | MK950 | Optimol
Chemical Information
Molecular Formula C13H24N4O3S
CAS Registry Number 26839-75-8
SMILES CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperkalaemia14.05.03.0010.000150%
Hypersensitivity10.01.03.0030.001705%
Hypertension24.08.02.001--
Hypoaesthesia eye17.02.06.019; 06.01.01.007--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000150%
Hypotension24.06.03.0020.000301%
Hypothermia12.05.03.001; 08.05.01.0030.000301%
Hypoxia22.02.02.0030.000100%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Intermittent claudication24.04.03.001--Not Available
Keratitis06.04.02.002--
Lacrimation disorder06.08.02.010--Not Available
Lacrimation increased06.08.02.0040.000321%
Laryngospasm22.04.02.002--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000150%
Libido decreased19.08.03.001; 21.03.02.005--
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.000401%Not Available
Macular oedema06.04.06.005--Not Available
Memory impairment17.03.02.003; 19.20.01.003--
Metabolic acidosis14.01.01.0030.000100%Not Available
Mood swings19.04.03.001--Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000100%
Myalgia15.05.02.001--
Myasthenia gravis15.05.08.001; 10.04.05.001; 17.05.04.001--
Myocardial infarction24.04.04.009; 02.02.02.0070.000100%
Nasal congestion22.04.04.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene